Zhaoke Ophthalmology Limited

HKSE 6622.HK

Zhaoke Ophthalmology Limited EBITDA for the year ending December 31, 2023: USD -46.18 M

Zhaoke Ophthalmology Limited EBITDA is USD -46.18 M for the year ending December 31, 2023, a 13.66% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Zhaoke Ophthalmology Limited EBITDA for the year ending December 31, 2022 was USD -53.49 M, a 9.98% change year over year.
Zhaoke Ophthalmology Limited EBITDA for the year ending December 31, 2021 was USD -59.42 M, a -285.12% change year over year.
Zhaoke Ophthalmology Limited EBITDA for the year ending December 31, 2020 was USD -15.43 M, a -24.24% change year over year.
Zhaoke Ophthalmology Limited EBITDA for the year ending December 31, 2019 was USD -12.42 M, a -195.40% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

HKSE: 6622.HK

Zhaoke Ophthalmology Limited

CEO	Dr. Xiaoyi Li Ph.D.
IPO Date	April 29, 2021
Location	China
Headquarters	No. 1 Meide 3rd Road
Employees	297
Sector	Health Care
Industries Pharmaceuticals Eyewear

Description

Zhaoke Ophthalmology Limited, an ophthalmic pharmaceutical company, engages in the research, development, and commercialization of therapies that address unmet medical needs in the People's Republic of China. It is developing various drugs that cover ophthalmic indications affecting the anterior and posterior segments, including dry eye diseases, wet age-related macular degeneration, diabetic macular edema, myopia, and glaucoma. The company was formerly known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited was incorporated in 2017 and is headquartered in Guangzhou, the People's Republic of China.

Key trends

Past 5 years